BeiGene Ltd's (6160) shares surged 7.74% in the intraday trading session on Friday, riding on the crest of robust revenue growth and a promising outlook for the oncology treatments developer.
The Hong Kong-listed stock hit a three-year high of HK$174.8, reflecting investors' enthusiasm for the company's stellar performance. BeiGene reported a remarkable 78% year-over-year increase in total global revenues to $1.1 billion for the fourth quarter of 2024 and a 55% year-over-year increase to $3.8 billion for the full year.
Adding to the optimism, the company provided full-year 2025 revenue guidance of $4.9 billion to $5.3 billion, underscoring its confidence in sustained growth. Nomura analysts, who have a "Buy" rating on the stock, praised the Q4 2024 sales beat, attributing it to balanced growth across the US, China, and EU markets.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。